Premium
Everolimus eluting bioresorbable vascular scaffolds for infrapopliteal critical limb ischemia: Moving beyond grasping at metal straws
Author(s) -
Winscott John G.,
Hillegass William B.
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29451
Subject(s) - medicine , critical limb ischemia , percutaneous , revascularization , angioplasty , bioresorbable scaffold , bare metal , balloon , everolimus , limb ischemia , cutting balloon , stent , thrombosis , surgery , target lesion , ischemia , restenosis , radiology , cardiology , myocardial infarction , percutaneous coronary intervention
Key Points Consistent and durable patency and clinical benefit after initially successful infrapopliteal percutaneous balloon transluminal angioplasty (PTA) for critical limb ischemia remains an unmet need. Permanently implanted metallic stents for suboptimal initial infrapopliteal PTA results also have limited patency and clinical results as well as other drawbacks. In 48 critical limb ischemia patients with infrapopliteal lesions < 50 mm length, everolimus eluting bioresorbable vascular scaffolds (EEBVS) achieved 90% primary patency and freedom from clinically driven target lesion revascularization at 2 years follow‐up with no late scaffold thrombosis.